Patents by Inventor Gabriele Marcolongo

Gabriele Marcolongo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220409570
    Abstract: A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 29, 2022
    Applicant: EPITECH GROUP S.P.A.
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Chiara GOMIERO, Gabriele MARCOLONGO, Salvatore CUZZOCREA
  • Publication number: 20220378725
    Abstract: A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): oleoylethanolamide (OEA) C18:1 60-65%? palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0 ?1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8%? myristoylethanolamide (MEA) C14:0 0.02-0.15%?? mixture of glycerides ?4-6% glycerol ?6-8%. A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 1, 2022
    Applicant: EPITECH GROUP S.P.A.
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Gabriele MARCOLONGO, Chiara GOMIERO
  • Patent number: 11491122
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 8, 2022
    Assignee: Epitech Group S.p.A.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Publication number: 20220304954
    Abstract: The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 29, 2022
    Applicant: Epitech Group S.p.A.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Giuliano Claps, Chiara Gomiero, Vito Safina
  • Publication number: 20220304956
    Abstract: The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 29, 2022
    Applicant: Epitech Group S.p.A.
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Gabriele MARCOLONGO, Giuliano CLAPS, Chiara GOMIERO, Vito SAFINA, Annalisa NOCE, Salvatore CUZZOCREA, Giuseppe ESPOSITO
  • Publication number: 20210308160
    Abstract: The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 7, 2021
    Applicant: Innovet Italia S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Sofia Parrasia, Salvatore Cuzzocrea
  • Publication number: 20210060047
    Abstract: Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.
    Type: Application
    Filed: August 25, 2020
    Publication date: March 4, 2021
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Gabriele MARCOLONGO, Salvatore CUZZOCREA, Vito SAFINA
  • Publication number: 20190290669
    Abstract: The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicant: Innovet Italia S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Sofia Parrasia, Salvatore Cuzzocrea
  • Publication number: 20190224145
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: Epitech Group S.p.A.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Publication number: 20170209395
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Epitech Group S.r.l.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Patent number: 9522192
    Abstract: The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues—particularly in the skin and mucosae—and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: December 20, 2016
    Assignee: EPITECH GROUP S.r.l.
    Inventors: Antonio Calignano, Giuseppe D'Agostino, Sonia Laneri, Rosaria Meli, Carmine Ostacolo, Roberto Russo, Antonia Sacchi, Diana Tronino, Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo
  • Patent number: 9512091
    Abstract: The present invention regards compositions and methods for the modulation of amidases capable of hydrolyzing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: —CH3, —CH2OH, —COOCH3, —COOH. Y may preferably be: —CH2—CH2—, —CH2—CH2—CH2—, CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH2—C(CH3)2—, —CH2—CH(CH2OH)—, —CH2—C((CH2OH)2)—, —CH?CH—, —CH2—CH(COOCH3)—, —CH2—CH(COOH)—, for use as a medicine.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: December 6, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Vincenzo Di Marzo, Salvatore Cuzzocrea
  • Patent number: 9399031
    Abstract: A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: July 26, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea
  • Publication number: 20160045529
    Abstract: The described herein is a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide and Cytidinediphosphocholine for the treatment of pathologies of the Central Nervous System of a traumatic, vascular, degenerative nature associated with neurodegeneration. The pharmaceutical composition containing palmitoylethanolamide (PEA) and Cytidinediphosphocholine (CDP-Choline or Citicoline), possibly with the addition of an antioxidant compound such as for example a polyphenol, alpha-lipoic acid or L-acetylcysteine.
    Type: Application
    Filed: August 12, 2015
    Publication date: February 18, 2016
    Applicant: EPITECH GROUP S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea
  • Publication number: 20160008301
    Abstract: The described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 14, 2016
    Applicant: Epitech Group S.r.l.
    Inventors: Maria Federica DELLA VALLE, Francesco DELLA VALLE, Vincenzo DI MARZO, Stefania PETROSINO, Barbara COSTA, Gabriele MARCOLONGO, Daniele GRASSI
  • Publication number: 20150157733
    Abstract: The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues—particularly in the skin and mucosae—and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects.
    Type: Application
    Filed: December 11, 2013
    Publication date: June 11, 2015
    Inventors: Antonio CALIGNANO, Giuseppe D'AGOSTINO, Sonia LANERI, Rosaria MELI, Carmine OSTACOLO, Roberto RUSSO, Antonia SACCHI, Diana TRONINO, Francesco DELLA VALLE, Maria Federica DELLA VALLE, Gabriele MARCOLONGO
  • Publication number: 20150057269
    Abstract: The present invention regards compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: —CH3, —CH2OH, —COOCH3, —COOH. Y may preferably be: —CH2—CH2—, —CH2—CH2—CH2—, CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH2—C(CH3)2—, —CH2—CH(CH2OH)—, —CH2—C((CH2OH)2)—, —CH?CH—, —CH2—CH(COOCH3)—, —CH2—CH(COOH)—, for use as a medicine.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 26, 2015
    Applicant: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Vincenzo Di Marzo, Salvatore Cuzzocrea
  • Publication number: 20150011617
    Abstract: A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Applicant: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea
  • Patent number: 8877284
    Abstract: A method for making a flexible and clear plastics material article of manufacture having a low electric surface resistance, starting from a plastics material having a higher electric surface resistance, in which the electric surface conductivity of the starting article of manufacture is modified by partially including, into at least a portion of the outer surface of the article, carbon nanotubes. With respect to conventional methods, the inventive method allows to modify the starting plastics material electric surface resistance so as to lower it to values smaller than 102 k?/sq, even starting from articles having a higher resistance of the order of 1013 k?/sq, while preserving the starting clearness and flexibility thereof.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: November 4, 2014
    Assignee: IVG Colbachini S.p.A.
    Inventors: Gabriele Marcolongo, Moreno Meneghetti
  • Patent number: 8663701
    Abstract: The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: March 4, 2014
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Gabriele Marcolongo, Maria Federica Della Valle